BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 374 participants.

Also called NCT07628985

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 374 participants (planned count) (from the registry)
Sponsor
Carnot Laboratories (from the registry)
Registry
  • NCT NCT07628985
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Mexico (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07628985. Randomized; no masking; primary purpose treatment. Start 2026-09 (anticipated); primary completion 2027-10 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus (T2DM)
Intervention (Biological)
Bofanglutide
Intervention (Biological)
Semaglutide
Lead sponsor
Carnot Laboratories (class: industry)

Record details

Record id
cardio:ct-nct07628985
Content hash
3db9bc388f2c9c3d6003a5d0c094c6f4fa606347949d75d50974c16c7d2ebfe3